1. A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage– Related Complications in Allogeneic Transplantation 
Shotaro Tatekawa, Akio Kohno, Kazutaka Ozeki, Koichi Watamoto, Norihiro Ueda, Yohei Yamaguchi, Tsutomu Kobayashi, Isao Yokota, Satoshi Teramukai, Masafumi Taniwaki, Junya Kuroda, Yoshihisa Morishita 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 9, Pages (September 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
The cumulative incidences and numbers of TRCs. (A) The cumulative incidence of TRC-EC (), aGVHD (), and OC () by day 100 were 30.2%, 31.4%, and 16.0%, respectively. aGVHD included the patients who developed aGVHD alone as the first TRC, and the patients who developed GVHD with endothelial cell damage (GVHD-EC) were analyzed as TRC-EC. The individual cumulative incidence of TRC-EC (B), aGVHD (C), and OC (D) at any time point by day 100 were 30.3%, 54.1%, and 21.8%, respectively. (E) The numbers of patients who developed each TRC at any time points.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
The effect of the plasma levels of potential seven biomarkers to the development of TRC-EC and ROC curves for ANG2, CRP, D-dimer, TM, and sIL2R. (A) The plasma levels of angiopoietin 2 (ANG2), C-reactive protein (CRP), D-dimer, plasmin α2plasminogen inhibitor complex (PIC), soluble IL2 receptor (sIL2R), thrombomodulin (TM), and vascular endothelial growth factor (VEGF) were compared between patients with and without TRC-EC using a logistical regression model. (B) The AUC of each marker: ANG2 (), .91; CRP (), .78; D-dimer (), .85; TM (), .75; sIL2R (), .65.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The frequency distribution of patients according to the total score based on the composite panel. The number of patients with TRC-EC (n = 57) and without TRC-EC (n = 131) are shown in the bars based on the total score of the composite panel.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
OS and NRM based on the composite panel. The probability of overall survival (A) and cumulative incidence of nonrelapse mortality (B) are plotted according to the 3 groups; low (n = 61), intermediate (n = 44), and high (n = 44). The 5-year OS was 76.2%, 54.9%, and 26.9%, and the 5-year NRM was 7.1%, 16.3% and 61.3% for TRC patients in the low-, int-, and high-score groups, respectively. * = P < .05 and † = P < .01.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Supplemental Figure 1
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

7. Supplemental Figure 2
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions